Cancer Archives

News and Trends 11 Mar 2016

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located. City: Cambridge (UK) Founded: 2011 Employees: 30 Total raised: €110M (as of 02/2016) CEO: Anker Lundemose Mission: Founded in 2011, Mission Therapeutics, […]

March 11, 2016 - 1 minutemin - By Joachim Eeckhout

aprea ovarian cancer p53 protein apr 246 karolinska versant ventures 5am ventures healthcap

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

prime priority medicines ema european medicine agency breakthrough therapy fast track biotech

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

desktop genetics gene ngs illumina epigenetics

News and Trends 23 Feb 2016

UK Start-Up Gets €380k to Understand Cancer with CRISPR

Desktop Genetics, a small bioinformatics start-up out of London, has won a substantial grant to understand why some cancer cells just won’t quit. To do this, it relies on CRISPR, their expertise with genetic data, and research from Imperial College London. Desktop Genetics has already proven that it can move some money, with a €1.87 […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Feb 2016

Making Bladder Cancer Cells Glow earns French Biotech €1.5M

VitaDX (France), is developing a non-invasive medical device for early detection of bladder cancer, based on a syndicate of French academic research. This simple urine sample analysis has attracted over €1.5M in preparation for clinical trials and a global market launch. The technology operated by VitaDX is the result of a research collaboration between the Institute of Molecular […]

February 22, 2016 - 3 minutesmins - By Dani Bancroft

onxeo cancer beleodaq interview Judith Greciet

News and Trends 22 Feb 2016

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Last week, I was in Paris to meet with one of our Investors, during which time I also had a chance to visit the French Cancer Biotech, Onxeo. I met with the CEO of Onxeo, Judith Greciet, who was confident about the future of the company. She moved into the role in 2011 after having spent […]

February 22, 2016 - 4 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Subscribe to our newsletter

Advertise with us

Cancer

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

EMA Launches its own Fast Track for Breakthrough Therapies

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

New Joint Venture to Shake Up Immuno-Oncology in the UK

French Ipsen closes €700M deal for Californian Cancer Drug

German Biotech wins FDA Approval for New Liver Cancer Trial

UK Start-Up Gets €380k to Understand Cancer with CRISPR

Making Bladder Cancer Cells Glow earns French Biotech €1.5M

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!